sb 204070a has been researched along with nalbuphine in 1 studies
| Studies (sb 204070a) | Trials (sb 204070a) | Recent Studies (post-2010) (sb 204070a) | Studies (nalbuphine) | Trials (nalbuphine) | Recent Studies (post-2010) (nalbuphine) |
|---|---|---|---|---|---|
| 45 | 0 | 4 | 793 | 269 | 185 |
| Protein | Taxonomy | sb 204070a (IC50) | nalbuphine (IC50) |
|---|---|---|---|
| Mu-type opioid receptor | Homo sapiens (human) | 0.0578 | |
| Delta-type opioid receptor | Homo sapiens (human) | 1.1195 | |
| Kappa-type opioid receptor | Homo sapiens (human) | 0.097 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abdeen, S; Chapman, E; Chitre, S; Hoang, QQ; Johnson, SM; Park, Y; Ray, AM; Salim, N; Sivinski, J; Stevens, M; Washburn, A | 1 |
1 other study(ies) available for sb 204070a and nalbuphine
| Article | Year |
|---|---|
HSP60/10 chaperonin systems are inhibited by a variety of approved drugs, natural products, and known bioactive molecules.
Topics: Biological Products; Chaperonin 10; Chaperonin 60; Escherichia coli; Humans; Inhibitory Concentration 50; Protein Folding; Rafoxanide; Salicylanilides; Suramin | 2019 |